Balancing risk in ophthalmic prescribing: Assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 11, 2012, Pages 1563-1571

  Kaiser, Peter K ^a   Cruess, Alan F ^b   Bogaert, Peter ^c   Khunti, Kamlesh ^d   Kelly, Simon P ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Climate Change and Clean Technology Practice   (Belgium)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e ROYAL BOLTON HOSPITAL   (United Kingdom)

Author keywords

Age related macular degeneration; Bevacizumab; Medication safety; Off label prescribing; Ranibizumab

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ROSIGLITAZONE; VASCULOTROPIN INHIBITOR;

ARTERIAL THROMBOEMBOLISM; BLEEDING; CAUSE OF DEATH; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; EUROPEAN UNION; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OFF LABEL DRUG USE; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VASCULAR DISEASE; VEIN THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG; OFF-LABEL USE; PRESCRIPTION DRUGS; RISK ASSESSMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84871458216     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-2123-4     Document Type: Review

References (77)

1. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564-572
2. Wang JJ, Foran S,Mitchell P (2000)Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 28:268-273
3. Weih LM, Van Newkirk MR, McCarty CA, Taylor HR (2000) Agespecific causes of bilateral visual impairment. Arch Ophthalmol 118:264-269
4. Thanigaimani S, Kichenadasse G, Mangoni AA (2011) The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol 9:358-380
5. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
6. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular agerelated macular degeneration. Retina 26:859-870
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805-2816
8. Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606-2617
9. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T,Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398
10. Rakic JM,LambertV, Devy L, LuttunA, Carmeliet P, ClaesC,Nguyen L, Foidart JM, Noel A, Munaut C (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186-3193
11. Novartis. Lucentis prescribing information. Available at http://www.lucentis.co.uk/DMO/PrescribingInformation.html. Accessed 13 June 2012
12. Genentech. Lucentis prescribing information, 2010. Available at http://www.gene.com/gene/products/information/pdf/lucentisprescribing.pdf. Accessed 25 May 2010
13. Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803- 2812
14. van Wijngaarden P, Qureshi SH (2008) Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom 91:427-437
15. Medicines and Healthcare products Regulatory Agency. Drug safety update: Off-label or unlicenced use of medicines: prescribers' responsibilities, 2009. Available at http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON087990. Accessed 11 October 2011
16. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 364:1897-1908
17. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388-1398
18. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: oneyear findings from the IVAN randomized trial. Ophthalmology. 119:1399-1411
19. National Audit Office. The Management and Control of Hospital Acquired Infection in Acute NHS Trusts in England, 2000. Available at http://www.nao.org.uk/publications/9900/hospital-acquired-infection.aspx. Accessed 20 September 2011
20. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205
21. Medicines and Healthcare products Regulatory Agency: Annual statistics 2009/10. Available at www.mhra.gov.uk/home/idcplg?IdcService=GET- FILE&dDocName=CON090868&RevisionSelectionMethod=LatestReleased. Accessed 20 September 2011
22. Department of Health. An organisation with a memory - report of an expert group on learning from adverse events in the NHS chaired by the Chief Medical Officer, 2000. Available at http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-4065083. Accessed 20 September 2011
23. Kelly SP, Barua A (2011) A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. Eye 25(6):710-716
24. Backstrom M, Mjorndal T, Dahlqvist R (2004) Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 13:483-487
25. Csaky K, Do DV (2009) Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal antivascular endothelial growth factor therapies. Am J Ophthalmol 148:647-656
26. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471
27. Rosen CJ (2007) The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med 357:844-846
28. Rosen CJ (2010) Revisiting the rosiglitazone story - lessons learned. N Engl J Med 363:803-806
29. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411-418
30. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731
31. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH (2008) Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 168:2368-2375
32. Killick J, Berghe P (2009) Does promoting off-label use of medicines on budgetary grounds risk jeopardising the integrity of the marketing authorisation requirement system? Pharmaceutical Law Insight 6:4-5
33. Directive 2001/83/EC of the European Parliament and of the council of 6 November 2001 on the community code relating to medicinal products for human use. Available at http://www.ema.europa.eu/docs/en-GB/document-library/ Regulatory-and-procedural-guideline/2009/10/WC500004481.pdf. Accessed 20 September 2011
34. Shah RR (2001) Thalidomide, drug safety and early drug regulation in the UK. Adverse Drug React Toxicol Rev 20:199-255
35. European Medicines Agency. Guideline on compassionate use of medicinal products, pursuant to article 83 of regulation (EC) No 726/2004, 2007. Committee for medicinal products for human use Doc. Ref: EMEA/27170/22006
36. Molyneux C, Bogaert P (2010) The need for informed consent in off-label use in the EU. Regulatory Affairs Pharma November:13- 16]
37. Weynants L, Schoonderbeek C (2010) Off-label use and promotion in the EU: risks and potential liability. Regulatory Affairs Pharma November:7-12]
38. General Medical Council. Good practice in prescribing medicines 2008. Available at http://www.gmc-uk.org/static/documents/content/GMP-0910.pdf. Accessed 20 September 2011
39. Federazione nazionale degli ordini dei medici chirurghi e degli odontoiatri: Codice di deontologia medica (Italian code of medical ethics), 2006. Available at http://www.ordinemedici-go.it/codice.pdf. Accessed 20 September 2011
40. German Medical Association: Professional code for physicians in Germany, 2006. Available at http://www.bundesaerztekammer.de/page.asp?his=1.100.1143. Accessed 20 Spetember 2011
41. Spanish Ministry of Health and Social Policy: Royal Decree 1015/2009, 2009. Available at http://boe.es/boe/dias/2009/07/20/pdfs/BOE-A-2009-12002.pdf. Accessed 20 September 2011
42. Code de la santé publique (French public health code), 2010. Available at http://www.legifrance.gouv.fr/affichCode.do?idArticle= LEGIARTI000006912859&idSectionTA=LEGISCTA000006196408&cidTexte= LEGITEXT000006072665&dateTexte=20080314. Accessed 20 September 2011
43. General Medical Council. Consent: patients and doctors making decisions together, 2008. Available at http://www.gmc-uk.org/static/documents/content/ Consent-0510.pdf. Accessed 20 September 2011
44. General Medical Council. Good practice in prescribing medicines - supplementary guidance 2008. Available at http://www.gmc-uk. org/static/documents/content/Good-Practice-in-Prescribing-Medicines-0911.pdf. Accessed 20 September 2011
45. Riley JB, Basilius PA (2007) Physicians' liability for off-label prescriptions. Haematol & Oncol News & Issues May/June: 24-37
46. Court of Justice of the European Union. C-185/10 - European Commission versus Poland. Available at http://curia.europa.eu/juris/liste.jsf?language= en&jur=C,T,F&num=c-185/10&td=ALL. Accessed 13 June 2012
47. Ferroni P, Formica V, Roselli M, Guadagni F (2010) Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol 8:102-113
48. Genentech. Avastin prescribing information, 2011. Available at http://www.gene.com/gene/products/information/pdf/avastinprescribing. pdf. Accessed 20 September 2011
49. Hu CC, Ho JD, Lin HC (2010) Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. Stroke 41:613-617
50. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR (2007) Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Ophthalmology 114:86-91
51. Wong TY, Klein R, Sun C, Mitchell P, Couper DJ, Lai H, Hubbard LD, Sharrett AR (2006) Age-related macular degeneration and risk for stroke. Ann Intern Med 145:98-106
52. Meyer CH, Holz FG (2011) Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye 25:661-672
53. European Medicines Agency. Lucentis European public assessment report, scientific discussion, 2007. Available at http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/000715/human-med-000890.jsp&murl= menus/medicines/medicines.jsp&mid=WC0b01ac058001d124. Accessed May 2011
54. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850
55. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182
56. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855-859
57. Meyer CH, Krohne TU, Holz FG (2011) Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 31:1877-1884
58. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94:1215-1218
59. Carneiro AM, Costa R, Falcao MS, Barthelmes D, Mendonça LS, Fonseca SL, Gonçalves R, Gonçalves C, Falcao-Reis FM, Soares R (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25-e30
60. Carneiro AM, Barthelmes D, Falcao MS, Mendonca LS, Fonseca SL, Goncalves RM, Faria-Correia F, Falcao-Reis FM (2011) Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 225:211-221
61. Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128:1273-1279
62. Gower EW, Cassard C, Chu L, Varma R, Klein R Adverse event rates following intravitreal injection of Avastin or Lucentis for treating age-related macular degeneration. Presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, 3rd May 2011
63. Smith AF (2010) The growing importance of pharmacoeconomics: the case of age-related macular degeneration. Br J Ophthalmol 94:1116-1117
64. USP28/NF23 (2005) Particulate matter in ophthalmic solutions. United States Pharmacopeial Convention, Inc., Rockville, MD, Chapter 789
65. USP28/NF23 (2005) Particulate matter in injections United States Pharmacopeial Convention, Inc., Rockville, MD, Chapter 788
66. Ornek K, Karahan ZC, Ergin A, Tekeli A, Tekeli O (2008) Bevacizumab sterility in multiple doses from a single-use vial. Ann Pharmacother 42:1425-1428
67. Kahook MY, Liu L, Ruzycki P, Mandava N, Carpenter JF, Petrash JM, Ammar DA (2010) High-molecular-weight aggregates in repackaged bevacizumab. Retina 30:887-892
68. The Royal College of Ophthalmologists. Potential bevacizumabrelated sterile endophthalmitis cases - update, 23 April, 2012. Available at http://www.rcophth.ac.uk/news.asp?itemid=781&itemTitle= Potential+bevacizumab%2Drelated+sterile+endophthalmitis+cases+%96+update%2C+23+ April§ion=24§ionTitle=News. Accessed 18 June 2012
69. Kairuz TE, Gargiulo D, Bunt C, Garg S (2007) Quality, safety and efficacy in the 'off-label' use of medicines. Curr Drug Saf 2:89-95
70. Sun X, Xu X, Zhang X (2011) Counterfeit bevacizumab and endophthalmitis. N Engl J Med 365:378-379. doi:10.1056/NEJMc1106415#SA1, author reply 379
71. FDA alerts health care professionals of infection risk from repackaged Avastin intravitreal injections. Available at http://www.fda.gov/Drugs/ DrugSafety/ucm270296.htm Accessed 30 August 2011
72. Medical Products Agency - Sweden. Position of the Medical Products Agency regarding Lucentis and Avastin, 2012. Available at http://www.lakemedelsverket. se/english/All-news/NYHETER-2012/Position-of-the-Medical-Products-Agency- Regarding-/. Accessed 16 March 2012
73. Saluter: the portal of the Emilia-Romagna region. Determinazioni in merito alla propria deliberazione n. 1628/2009 concernente l'erogabilità del medicinale Bevacizumab a carico del Ssr. Available at http://www.saluter.it/ documentazione/ptr/ptr/dgr-186-2012%20-sospensione-uso-avastin.pdf/view? searchterm=avastin. Accessed June 13 2012
74. Current opinion of the German Ophthalmological Society, the Retinological Society, and the Professional Association of German Ophthalmologists. New aspects in the treatment of neovascular age-related macular degeneration, 2009. Available at http://www.dog.org/wp-content/uploads/2009/08/Stellungnahme- Makuladegeneration-200903.pdf. Accessed 13 June 2012
75. Current opinion of the German Ophthalmological Society, the Retinological Society, and the Professional Association of German Ophthalmologists. The anti-VEGF therapy for neovascular age-relatedmacular degeneration: Therapeutic Strategies, 2012. Available at http://www.dog.org/wp-content/uploads/2009/08/ Stellungnahme-Anti-VEGF-Therapie-bei-der-neovaskul%C3%A4ren-Therapeutische- Strategie-Febr-2012-final1.pdf. Accessed 25 June 2012
76. The Royal College of Opthalmologists. Bevacizumab (Avastin) use in medical ophthalmology, 2011. Available at http://www.rcophth.ac.uk/core/core- picker/download.asp?id=1181. Accessed 18 June 2012
77. Regulation (EU) No 1235/2010 of the European Parliament and of the council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products., 2010. Available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016: EN:PDF. Accessed 13 June 2012